MTX-531 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors. The study will evaluate the safety and tolerability of MTX-531, determine the maximum tolerated dose and recommended Phase 2 dose, and assess how the drug is processed by the body and its preliminary anti-tumor activity.
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, such as colon, endometrial, breast, or head and neck cancers, whose disease has not responded to standard treatments. Participants must be in generally stable health aside from their cancer.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- MTX-531
Trial Overview
The study is testing MTX-531, a new drug that blocks EGFR and PI3K pathways involved in cancer growth. It aims to find the safest dose and see how the body handles the drug. All participants receive MTX-531.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants receive MTX-531 as monotherapy in sequential dose levels to evaluate the safety and tolerability of MTX-531, determine the maximum tolerated dose and recommended Phase 2 dose, and assess pharmacokinetics and preliminary clinical activity.
Find a Clinic Near You
Who Is Running the Clinical Trial?
MEKanistic Therapeutics, Inc.
Lead Sponsor
Translational Drug Development
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.